Logo
Logo

Our Sustainability and ESG Goals

Dr. Reddy's integrated annual and sustainability report for the Fiscal Year 2025 is out. This edition acknowledges 40 years of Dr. Reddy's by taking you through our most significant milestones.

Access

Access

To serve as many patients as possible across the world.

Affordability

Affordability

Operational excellence and productivity to deliver care affordably to patients.

Patient-centric Innovation

Patient-centric Innovation

Focused innovation to identify and address unmet needs of patients.

Our progress was recognized in our ascent to the Dow Jones Sustainability World Index, improved position in the S&P Global Sustainability Yearbook, and silver medal status by EcoVadis.

We scored “A” in Climate Change & Supplier Engagement and “A” in Water Security. We are the only Indian pharmaceutical company to achieve CDP’s Leadership Band rating of A/A– in Climate Change, Water Security & Supplier Engagement (only 2% of companies globally received an “A” in 2024). 
 

Sustainability

Sustainability is deeply embedded in our purpose and forms the core of our organization.

Our journey began with APIs in 1984, and we evolved from small molecules to large molecules and from APIs to finished formulations over the decades. Amidst this evolution, what has remained constant at the heart of our organization is a deep commitment to patients and the customers we serve through our core principles of collaboration and sustainability.

By the end of FY2025, we had served over 756 million patients and continue our endeavours to reach over 1.5 billion patients globally by 2030. This means almost one in every five people on this planet will use Dr. Reddy’s product or service. The health of people is strongly linked to the health of our planet. That's why our integrated report also shows how sustainability and business are strongly linked.

Our ESG (Environment, Social & Governance) Goals:

Building the future responsibly

Our ESG goals are deeply embedded in our business strategy, guiding our efforts to create a significant and lasting positive impact on the planet and its people. We have made fair progress across several of these goals, even as a few continue to present challenges. We are committed to advancing our ESG journey, ensuring that as we prosper, we do so responsibly and with resilience.

Environment – Planet First

ThemeDescriptionTargetFY 2025 Progress
Reducing carbon emissionsAdopting renewable power100% renewable power by 203068% of our power was through renewable sources
Progressing towards carbon neutralityCarbon neutrality in our direct operations (Scope 1 & Scope 2) by 203060% Carbon neutrality Achieved so far
Reducing carbon emissions in the supply chain12.5% reduction in indirect carbon emissions across our supply chain (Scope 3 emissions) by 20305% decrease in reported Scope 3 emissions against FY2021
Water PositivityTo be a water positive organisationBe water positive by 2025Continued to be a water positive company post achieving the target in FY2023
AccessServing maximum patients with careServe 1.5 billion patients by 2030~756 million patients served
AffordabilityIntroducing first-to-market solutions*40% of our new launches to be first-to-market in our #priority markets by 203029%
InnovationImproving treatment standards regularly3 innovative solutions every year from 2027 to improve the standard of treatmentToripalimab and Evenity launched in India
Equitable Growth
ThemeDescriptionTargetFY 2025 Progress
Diversity, equity, and inclusion Enhancing women leadership At least 35% women in senior Leadership by 203020.4%
Promoting gender parity Gender parity by 2035 21.8%
Equal opportunity for the persons with disabilities (PhDs)Include at least 3% persons with disabilities (PwD) in our workforce by 20300.43%

Governance – Trusted Relationships

ThemeDescriptionTargetFY 2025 Progress
Corporate Governance Committed to upholding the highest standards of compliance and ethicsMeet the highest standards on compliance and ethics backed by Robust corporate governanceZero material deviations recorded During the year
ESG DisclosuresTransparency and communication around our ESG performanceEnhance disclosure on our ESG progress to reach the top Quartile by 2025Enhanced ESG disclosures with wider coverage of KPIs, increased reporting frameworks, and double materiality assessment
Strategic SuppliersEmbedding ESG principles across our supply chain100% strategic suppliers to be compliant with our chosen ESG framework by 203073% of strategic suppliers (India Spend) assessed

Our ESG (Environment, Social & Governance) Goals:

Being committed to environmental stewardship

Being committed to environmental stewardship

    • Reducing carbon emissions
      • 100% renewable power by 2030
      • Carbon neutrality in our direct operations (Scope 1 & Scope 2) by 2030
      • 12.5% reduction in indirect carbon emissions across our supply chain (Scope 3 emissions) by 2030
    • Reducing carbon emissions
      • 100% renewable power by 2030
      • Carbon neutrality in our direct operations (Scope 1 & Scope 2) by 2030
      • 12.5% reduction in indirect carbon emissions across our supply chain (Scope 3 emissions) by 2030
Making our products accessible and affordable for patients

Making our products accessible and affordable for patients

    • Access
      • Serve 1.5 billion patients by 2030.
    • Affordability
      • 25% of our new-launches to be first-to-market by 2027.
    • Innovation
      • 3 innovative solutions to improve the standard of treatment every year from 2027.
Contributing to a fairer and more socially inclusive world

Contributing to a fairer and more socially inclusive world

    • Equity, diversity, and inclusion
      • At least 35% women in senior leadership by 2030
      • Gender parity by 2035
      • Include at least 3% persons with disabilities (PwD) in our workforce by 2030.
      • 100% living wages for our on-premises extended workforce by 2025.
Enhancing trust with our stakeholders

Enhancing trust with our stakeholders

    • Highest standards of compliance
      • Meet the highest standards on compliance and ethics backed by robust corporate governance ESG disclosures.
      • ESG Disclosures: Progressively enhance disclosure on our ESG progress to reach top quartile by 2025.
      • Strategic Suppliers: 100% strategic suppliers to be compliant with our ESG framework by 2030.
    • Affordability
    • Innovation

What we achieved in the past year:

product

3.8

Bn total revenue (17% growth)

product

165

New products launched

product

111

DMFs filed, (1,630+ Cumulative DMFs)

product

249

Dossiers, including 10 ANDAs filed

product

76

Filings in the US pending for approval

product

20.4%

Women in leadership

product

96%

Employees trained for skill upgradation

product

0.14 to 0.07

*LTIFR reduced from


product

126

Differently abled employees

product

700,000+

Lives impacted through CSR

product

783

Million KL of water saved through agri-water saving techniques

product

66,723

MTCO2e of direct emissions reduction

product

11%

Reduction in water intensity per rupee of turnover with respect to FY2024

product

60%

Carbon neutrality achieved

product

75,761

KL of harvested rainwater used

product

54%

Water reused/recycled

Sustainability & Green Chemistry in Dr. Reddys API Operations
oncology partical

Sustainability & Green Chemistry in Dr. Reddys API Operations

ESG in the pharmaceutical industry is an essential prerequisite. In our core API business, our focus on innovation-led affordability gives our customers access to the most complex active ingredients, while maintaining their drug development needs has also given an edge to our own generics business, enabling us to deliver higher quality at competitive costs.
We are present across multiple channels, with customer engagements along different points in the development and manufacturing value chain—from discovery and CDMO (Contract Development and Manufacturing Organization) services to development, manufacture, and sales. Through integrated discovery and CDMO services, we have executed more than 500 projects over 20 years.


Green Chemistry:

  • 15–18% improvement in Process Mass Intensity (PMI).
  • 20–22% waste reduction for 9 high-volume products.
  • No use of hazardous solvents like acetonitrile in the 8 evaluated products.
  • In-house capabilities to apply green chemistry principles.
  • Focus on reducing hazardous substances and improving sustainability.


Sustainability:

  • Focus on energy efficiency, water conservation, and waste reduction.
  • Adoption of low-temperature evaporator (LTE) technology replacing conventional systems.
  • Implementation of membrane bioreactor (MBR) systems for improved water treatment.


Environmental Impact:

  • Lifecycle Assessment (LCA) conducted for Sitagliptin HCL and Quetiapine Fumarate APIs.
  • Water conservation and reuse initiatives at API sites.

 

 

call big icon

国別の要件がある場合は、お手伝いいたします。

Highlights for the year

API (Develop, manufacture, and sell APIs to customers globally)

  • 1650+ active drug master files (DMFs).
  • 65+ products in pipeline.
  • 111 DMFs filed in FY 24

API+ (Institutional and B2B sales of value-added offerings above the API)

  • Currently in 25+ countries
Doctor with hologram

Our Community Initiatives

Education

Education

    • Enhance the quality of education and provide equal learning opportunities to the children from the marginalised communities through:
      • Kallam Anji Reddy Vidyalaya and Junior Vocational College
      • School Improvement Programme (SIP)
      • Sashakt scholarship for girls
Livelihood

Livelihood

    • Provide skills to youth for enhancing their employability and to enhance livelihoods by extending support to small and marginal farmers through:
      • Placement-linked skilling programme for youths and Persons with Disability
      • Healthcare Skilling in the non–medical healthcare sector
      • Agriculture programme focusing on capacity and income enhancement of small and marginalised farmers.
Health

Health

    • Making healthcare accessible and affordable, and reliable for the communities through:
      • Rural healthcare services at the doorstep through the Community Health Intervention Program
      • Tele-counselling support for mental health through the Roshni Helpline
      • Include at least 3% persons with disabilities (PwD) in our workforce by 2030.
      • Improving primary healthcare services to improve the quality of primary care services in the selected Primary Healthcare Centres
  •  Environmental Sustainability
    icon

    Environmental Sustainability

    Promoting sustainable agriculture practices and wildlife conservation through:Climate Smart Agriculture and Regenerative Agriculture practicesConserving Tigers and their habitat in the Eastern Ghats.Sustainability in the pharma industry is a vital aspect. Our strength in innovation, ethical values, and focus on bringing critical, life-saving products early to market secures a unique kind of sustainability for us. In addition, our leadership across global markets indicates our strong alignment with our & Good Health Can’t Wait agenda.Pharmaceutical companies’ sustainability is an increasingly important topic for the entire world. While we renewed our goals in 2023 to adapt to changing stakeholder expectations, address climate change, and our resolve to work on material issues, we continued to examine more ways to make an impact. We consulted a more extensive set of global pharmaceutical sustainability and pharmaceutical standards and frameworks, and these findings guided our ESG reviews with the leadership and Board.Combining a top-down and bottom-up approach, using more tools such...

  •  Our Sustainability Framework
    icon

    Our Sustainability Framework

    At Dr. Reddy’s, we are committed to taking meaningful action for a sustainable future. With our long-standing commitment to protecting the environment, we are working on solutions that help minimize the impact of our operations, driving improvements in multiple areas at various stages of the product life cycle.Looking at issues of maximum importance to our stakeholders and the business, we are in the process of identifying material issues and building our strategic sustainability framework. We will develop ambitious goals and management targets for each focus area, with multiple milestones, incorporating governance systems and processes, monitoring, and disclosing our performance for each goal, and ensuring independent third-party assurance.We are determined to play our part in upholding the more prominent global perspective and sustainable development in pharmaceutical industry. We will align ourselves with the United Nations sustainable development goals (UN SDGs), mapping them with our top material issues, allocating internal resources, taking...

  • R&D Operations Guided by Sustainability Framework
    icon

    R&D Operations Guided by Sustainability Framework

    Since 2010, Dr. Reddy’s has been committed to the UN Global compact corporate responsibility initiative and its principles in the environment, sustainability, and green chemistry. As an active pharmaceutical ingredient supplier, our primary goal is to develop products that will provide a reliable supply of products of superior quality for the pharmaceutical industry. Also, we ensure that our APIs are produced using eco-friendly processes so that our customers can sustainably access our APIs.

  • Robust Supply chain
    icon

    Robust Supply chain

    Our supply chain process is based on a strategic model to ensure a practical, reliable, and sustainable supply of goods and services based on a segmented operation. A scorecard is generated for all the KPIs, and we monitor the progress toward each goal. In addition, a well-defined Supplier Code of Conduct (SCOC) governs our supply chain management. We also have a dedicated SCM (Supply Chain Management) team that addresses all sustainable sourcing elements with special emphasis on supply continuity, quality and compliance, supplier relationships, capacity and capability building, supplier, and performance management, and aligning the partners with our vision of sustainability.Strong partner network - Intelligence to get early alerts on issues, enabling us to take corrective actions.Cross-industry collaboration groups - Support groups of transporters, shippers, airlines, etc. came together for information sharing and solutions.We are opening ourselves to new possibilities - Adopting new solutions such as moving cold chain products...

To know more about our Sustainability/ESG initiatives and programmes read our full sustainability report here.

Deepak Sapra,

Deepak Sapra,

CEO, Pharmaceutical Services & Active Ingredients.

"Sustainability is at the core of our mission at Dr. Reddy’s. We are committed to minimizing our environmental footprint, empowering communities, and ensuring ethical business practices. Together, we can build a healthier planet for future generations".

免責事項

このウェブサイト上のいかなる情報も、製品またはサービスへの言及を含め、販売の申し出を構成するものではなく、販売の申し出を表すものと解釈されるものでもありません。有効な特許により保護されている製品は、商用目的で提供または提供されるものではありません。ただし、特定のケースでは、Dr. Reddy の独自の裁量により、現地の法的要件に従って、そのような製品の研究用数量が、規制免除が存在する場所に、インド特許法第 107A 条 (Bolar 免除) に基づく規制提出の目的で提供される場合があります。購入者は、それぞれの市場における特許シナリオを含む製品またはサービスについて独自の評価を行う必要があり、すべての特許関連法的責任を負うことになります。Dr. Reddy は、商品性、特定目的への適合性、および非侵害の保証を含むがこれらに限定されない、明示または黙示を問わずすべての保証を否認します。